Non-Invasive Urine Test Improves Prediction of Bladder Cancer Treatment Outcomes: Study

A simple urine sample may soon reveal whether bladder cancer will return before scans can even detect it.

Bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC), is one of the most commonly diagnosed cancers and is notorious for coming back even after early treatment. Patients typically undergo tumor removal followed by immunotherapy using BCG. However, doctors have long lacked a reliable way to predict who will benefit from this therapy and who will relapse.

Now, a new study published in Cell by researchers at Stanford University offers a promising solution: a highly sensitive, non-invasive urine test that can detect microscopic traces of tumor DNA and predict recurrence risk with remarkable accuracy.

The innovation lies in overcoming a major challenge in liquid biopsy testing. Scientists discovered that even healthy bladder cells can carry mutations—termed “clonal cystopoiesis”—which can lead to false positives. To address this, the team developed a statistical method to filter out these background mutations, allowing the test to distinguish real cancer signals from harmless genetic noise.

When tested in patients undergoing surgery and BCG therapy, the results were striking. Individuals with detectable tumor DNA after treatment had an almost certain risk of recurrence, while those whose tumor DNA disappeared showed excellent outcomes. In many cases, the test identified relapse risk even before standard cystoscopy exams showed abnormalities.

Researchers also identified three response patterns: patients cured by surgery alone, those who responded to BCG, and those who did not respond to either. This insight could help doctors tailor treatment strategies more precisely.

If validated in larger trials, this approach could transform bladder cancer care—reducing unnecessary treatments, prioritizing high-risk patients, and enabling earlier intervention. Ultimately, it moves the field closer to truly personalized cancer therapy, guided by a simple urine test.

REFERENCE: Shi, W. Y., et al. (2026). Field-effect-informed urine liquid biopsy for bladder cancer. Cell. DOI: 10.1016/j.cell.2025.12.054. https://www.cell.com/cell/abstract/S0092-8674(25)01503-X